Business Context and Reporting Period
This Form 8-K Current Report was filed by Pavmed Inc. on December 5, 2023. The filing primarily addresses corporate governance actions taken to maintain the company's listing on The Nasdaq Stock Market LLC. The report details a 1-for-15 reverse stock split approved by the Board of Directors and previously ratified by stockholders, effective December 7, 2023.
Key Financial Metrics and Capital Structure
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The financial data provided relates strictly to capitalization and debt instrument adjustments:
- Authorized Common Stock: Reduced from 250,000,000 to 50,000,000 shares.
- Authorized Preferred Stock: Remains unchanged at 20,000,000 shares.
- Debt Adjustments: Conversion prices for Senior Secured Convertible Notes (dated April 4, 2022, and September 8, 2022) and Series B convertible preferred stock will be multiplied by 15.
- Warrant Adjustments: Series Z Warrants exercise prices will be multiplied by 15, and the number of shares exercisable will be divided by 15. The maturity date for Series Z Warrants is extended to April 30, 2025.
Material Changes Versus Prior Period
The primary material change is the implementation of a 1-for-15 reverse stock split. This action is a direct response to the company's failure to maintain the minimum $1.00 closing bid price required by Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days ending December 28, 2022. The company utilized the full 180-day initial compliance period and an additional 180-day extension granted by Nasdaq to effect this change.
Guidance, Outlook, and Material Events
Reason for Action: The reverse split is intended to increase the closing bid price of the common stock above $1.00 to regain and maintain Nasdaq listing compliance. The company expects the stock to trade on a split-adjusted basis starting December 7, 2023.
Lucid Diagnostics Dividend: On December 4, 2023, the company announced a dividend of approximately 3.3 million shares of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. Holders of the Senior Secured Convertible Notes waived their right to participate in this dividend on an as-converted basis.
Risks and Uncertainties: The filing includes forward-looking statements noting that no assurances can be provided that the reverse split will result in compliance with Nasdaq rules. The company must maintain a closing bid price above $1.00 for a minimum of ten consecutive business days to regain compliance.
Investor Verification Checklist
- Verify the post-split trading price of PAVM on December 7, 2023, to confirm if it exceeds the $1.00 threshold.
- Confirm the updated CUSIP number for the common stock (70387R 403) in brokerage accounts.
- Review the adjusted exercise prices and share counts for any held Series Z Warrants or convertible notes.
- Monitor subsequent Nasdaq communications regarding the company's compliance status following the ten-day observation period.